Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Kat Deng

Physician Assistant Mesa, AZ Physician Assistant

NPI 1245979558 CMS profile 11377992

2919 S Ellsworth Rd Ste 135, Mesa, AZ 85212

Open in the dashboard

General payments

$2,938

141 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kat Deng of Mesa, AZ is reported in the CMS Open Payments database as having received $2,938 across 141 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $286 13
2024 General $750 36
2023 General $860 39
2022 General $1,041 53

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kat Deng
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Kat Deng were reported at $286. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Kat Deng Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $1,041 $155 $48–$522 $149
2023 $860 $167 $52–$557 $160
2024 $750 $178 $55–$600 $164
2025 $286 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AbbVie, Inc. $500 24 payments
  2. Harmony Biosciences LLC $296 12 payments
  3. UCB, Inc. $266 11 payments
  4. Novartis Pharmaceuticals Corporation $247 14 payments
  5. Lilly USA, LLC $219 13 payments
  6. Jazz Pharmaceuticals Inc. $174 6 payments
  7. Biogen, Inc. $157 8 payments
  8. Argenx US, Inc. $117 6 payments
  9. SK Life Science, Inc. $106 4 payments
  10. Lundbeck LLC $86 4 payments
  11. Other $772 39 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $2,938 141 payments
Products named General payments · program years 2022–2025
  1. BOTOX Botox Therapeutic $234 10 payments
  2. QULIPTA $164 8 payments
  3. Briviact $157 8 payments
  4. XYWAV $142 5 payments
  5. WAKIX $129 5 payments
  6. KESIMPTA Neurology $129 6 payments
  7. KESIMPTA Neuroscience $118 8 payments
  8. VYVGART Hytrulo $117 6 payments
  9. BOTOX Hyperhydrosis $112 6 payments
  10. UBRELVY $109 6 payments
  11. Other $1,681 83 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 62 drugs

Part D claims

4,709

Median for Physician Assistant: 241

Drug cost

$856,131

Median for Physician Assistant: $4,110

Branded share of claims

23.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Aimovig Autoinjector Erenumab-Aooe Brand 144 $125,007
Briviact Brivaracetam Brand 67 $100,533
Ubrelvy Ubrogepant Brand 62 $79,907
Nurtec Odt Rimegepant Sulfate Brand 32 $62,473
Emgality Pen Galcanezumab-Gnlm Brand 56 $47,513
Fycompa Perampanel Brand 32 $41,071
Nourianz Istradefylline Brand 19 $39,139
Aptiom Eslicarbazepine Acetate Brand 14 $33,826
Lacosamide Generic 200 $29,612
Glatiramer Acetate Generic 13 $28,577

The 10 drugs with the highest cost, of 62 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $120
$120 — —
VYVGART Hytrulo
  • ARGENX US, INC. $70
$70 — —
KESIMPTA
  • Novartis Pharmaceuticals Corporation $67
$67 — —
AMYVID
  • Lilly USA, LLC $62
$62 — —
WAKIX
  • Harmony Biosciences LLC $59
$59 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

141 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record